

**Research Article****Cross sectional study on effect of aspirin on mortality  
in cases of tuberculous meningitis****Tayyab Nazir, Hafiz Tayyab Raza Jilane  
and Haider Ali**<sup>1</sup>Medical Officer, THQ Hospital Haroonabad<sup>2</sup>Medical Officer, THQ Hospital, Haroonabad<sup>3</sup>Medical Officer, BHU ChishtiQutab Din Tehsil Depalpur District Okara**ABSTRACT**

**Objectives:** To evaluate the effect of aspirin on mortality occurring within 2 months of starting treatment in tuberculous meningitis (TBM) stage III patients in patients 1-15 years of age.

**Study design:** A randomized open label placebo controlled trial

**Place and Duration of the study:** The study was conducted at THQ Hospital Haroonabad from March 2017 to September 2017.

**Patients and Methods:** A total of 162 patients of 1-15 years of age with TBM stage III were included in the study. Patients were divided in Group A (Aspirin group having 81 patients) and Group B (Placebo group having 81 patients). Outcome was noted in terms of mortality in both groups. All patients were treated with 4 antitubercular drug RHZE regimen (rifampicin 15mg/kg, isoniazid 10mg/kg, pyrazinamide 25mg/kg and ethambutol 15mg/kg) per oral daily for 2 months followed by RH (rifampicin 15mg/kg, isoniazid 10mg/kg) for 10 months along with corticosteroid (prednisolone 1-2mg/kg) per oral daily for 4 weeks and tapered in next 4 weeks. Oral aspirin was given to only group A patient at 60mg/kg per day divided 12 hourly starting with the first dose of antitubercular therapy.

**Results:** Out of a total of 162 children, there were 79 (48.8%) male and 83 (51.2%) female. Majority of the children, 106 (65.4%) were from 6 to 10 years of age. Miliary TB was found in 31 (19.1%) children. Presence of severe wasting was found amongst 40 (24.7%). Overall mortality was noted in 43 (26.5%) children. When both groups were divided, all the variables were found not to be statistically significant (p value > 0.05).

**Conclusion:** In children with TBM stage III, aspirin resulted in reduction in mortality but did not achieve statistical significance.

**INTRODUCTION:**

Tuberculosis (TB) is a global health issue. One third of the world population is infected with *Mycobacterium tuberculosis*; each year 9 million people develop disease and about 95% of the world's cases of TB occur in South East Asia, sub-Saharan Africa and Western Pacific. TB is the second leading killer after human immunodeficiency virus with annually about 2 million deaths; 10% of whom are younger than 15 years old. About 98% of those deaths occur in the developing countries of Asia and Africa<sup>1</sup>. In Pakistan approximately 5.7 million people suffer from TB, with 260,000 new cases occurring every year<sup>2</sup>. The exact population of

children with TB in Pakistan is unknown<sup>3</sup>. Tuberculous meningitis (TBM) is the most severe manifestation of tuberculosis in terms of high mortality and morbidity<sup>4</sup>.

Pathological manifestations of TBM are exudates, tuberculoma, hydrocephalus and stroke. Cerebrovascular complications of TBM that typically occur as multiple or bilateral lesions in the territories of middle cerebral artery perforating vessels are termed as tuberculous vasculopathy<sup>5</sup>. Vessel pathology appears to be a consequence of its immersion in the local inflammatory exudates leading to luminal thrombosis. There is some evidence that

vasospasm may mediate stroke early in the course of disease and proliferative intimal disease in later strokes.

The worst outcome of TBM is mainly due to the delay in diagnosis and mostly patient present at stage III<sup>6</sup>. Corticosteroids with antitubercular therapy were thought to reduce mortality and morbidity but their role in reducing strokes has not been proven. Aspirin also reduces mortality and its role in reducing stroke in TBM needs further studies<sup>7</sup>. One study is available with aspirin that showed reduction in stroke 24.2% compared to placebo group 43.3% and mortality 21.7% compared to placebo group 43.3%<sup>8</sup>.

I wanted to see the role of aspirin in reducing mortality in TBM in children as the available study includes both children and adults as no study was conducted previously on aspirin in Pakistan. TBM is not uncommon in Pakistan so we should try to search new drugs to improve the outcome.

#### **MATERIAL AND METHODS:**

This was a randomized controlled study, conducted at THQ Hospital Haroonabad from March 2017 to September 2017. Non probability consecutive sampling technique was used. All the patients of 1-15 years of age with TBM stage III were included. These criterias were confirmed by history, examination and investigations (Complete blood count (CBC) with platelets count, Prothrombin time (PT), Activated partial thromboplastin time (APTT), Bleeding time (BT), Liver function test (LFT's), renal function test (RFT's) and CT brain). Patients were excluded from the study who were on antitubercular treatment (by history), had bleeding diathesis (by history, examination and with platelets count, PT, APTT and BT), aspirin allergy (by history), liver disease (by history, examination and LFT's), kidney failure (by history, examination and RFT's) or subarachnoid hemorrhage (by examination and CT brain). The study was approved by the Institutional Ethical Committee. Children with TBM admitting in the ward through accident and emergency fulfilling the inclusion criteria were selected. Informed consent was taken from the parents / guardian. Randomization was done

by lottery method into group A (aspirin) and B (placebo). Demographic data as well as brief history and examination was documented on Performa (annex A). All patients were treated with 4 antitubercular drug RHZE regimen (rifampicin 15mg/kg, isoniazid 10mg/kg, pyrazinamide 25mg/kg and ethambutol 15mg/kg) per oral daily for 2 months followed by RH (rifampicin 15mg/kg, isoniazid 10mg/kg) for 10 months<sup>9</sup> along with corticosteroid (prednisolone 1-2mg/kg) per oral daily for 4 weeks and tapered in next 4 weeks. Oral aspirin was given to only group A patient at 60mg/kg per day divided 12 hourly starting with the first dose of antitubercular therapy. All the data was entered on a pre-designed Performa (annex A) for each patient.

Data was analyzed by using SPSS. Age was presented as mean and SD and outcome (mortality), gender were presented as frequencies and percentages. Effect modifiers were controlled by stratification of age (1-5 years, 6-10 years, and 11-15 years) sex, associated miliary tuberculosis (defined as millet like 1-5mm seeding of TB bacilli in the lung, as evident on chest x-ray), and patient with severe wasting (defined as a weight-for-length less than minus three SD). Chi square test was applied to compare the quantitative data (sex, mortality, presence of miliary TB, presence of severe wasting) and p value < 0.05 were taken as statistically significant.

#### **RESULTS**

Out of a total of 162 children, there were 79 (48.8%) male and 83 (51.2%) female. Mean age was 7.3 years with standard deviation of 3.07 years. Majority of the children, 106 (65.4%) were from 6 to 10 years of age while 37 (22.8%) 1 to 5 years and 19 (11.7%) 11 to 15 years of age. Miliary TB was found in 31 (19.1%) children. Presence of severe wasting was found amongst 40 (24.7%). Overall mortality was noted in 43 (26.5%) children. (Figure No.1)

When both groups were divided, there were 18 (22.2%) children from 1 to 5 years in Group A whereas 19 (23.6%) in Group B, 53 (65.4%) from 6 to 10 years in Group A and same in Group B, while 10 (12.3%) from 11 to 15 years

and 9 (11.1%) in Group B. After applying chi square, no statistical significance (p value = 0.961) was found between the both groups (Table No.1)


There were 37 (45.7%) male in Group A and 42 (51.9%) in Group B whereas 44 (54.3%) female in Group A and 39 (48.1%) in Group B. No statistical significance (p value = 0.432) was found between both the groups. (Table No.2)

As far as presence of miliary TB between the both groups is concerned, it was found 17 (21.0%) in Group A and 14 (17.3%) in Group B with an insignificant p value of 0.549. (Table No.3)

Presence of severe wasting was found in 18 (22.2%) children in Group A and 22 (27.2%) in Group B with an insignificant p value of 0.466. (Table No.3)

There were 18 (22.2%) children who died in Group while 25 (30.9%) in Group B. No statistical significance for mortality between the both groups was found as p value turned out to be 0.213. (Table No.3)

**Figure No.1:** Overall Mortality



**Table No.1:** Comparison of age between both the groups

Age (Years)	Groups		Total	P value
	A	B		
1-5	18 (22.2%)	19 (23.6%)	37 (22.8%)	0.961
6-10	53 (65.4%)	53 (65.4%)	106 (36.6%)	
11-15	10 (12.3%)	9 (11.1%)	19 (11.7%)	
<b>Total</b>	81 (50%)	81 (50%)	162 (100%)	

**Table No.2:** Distribution of Gender between both the groups

Gender	Groups		Total	P value
	A	B		
Male	37 (45.7%)	42 (51.9%)	79 (48.8%)	0.432
Female	44 (54.3%)	39 (48.1%)	83 (51.2%)	
<b>Total</b>	81	81	162	

**Table No.3:** Comparison of miliary TB, presence of severe wasting and mortality between both the groups

	Group A	Group B	P value
Miliary TB	17 (21.0%)	14 (17.3%)	0.549
Presence of Severe Wasting	18 (22.2%)	22 (27.2%)	0.466
Mortality	18 (22.2%)	25 (30.9%)	0.213

**DISCUSSION:**

The objective of present study was assess the effect of aspirin on mortality occurring within 2 months of starting treatment in tuberculous meningitis (TBM) stage III patients in patients 1-15 years of age. In current study, miliary TB was found in 17 (21.0%) children in Group A and 14 (17.3%) in Group B. Miliary TB could be an indicator for TBM in the countries with high prevalence of TB.<sup>10</sup> Concomitant miliary tuberculosis should bring TBM to mind in cases with an unknown origin. Female predominance, longer symptom duration, higher protein level in CSF may be remarkable in patients with TBM accompanied with miliary TB.<sup>11,12</sup>

Not many studies have evaluated the impact of aspirin on outcome of patients with TBM. In the present study, mortality was reduced in children who received aspirin (22.2%) as compared to those who were given placebo (30.9%). Although, there was reduction in terms of mortality in children who used aspirin but these results were not statistically significant (p value = 0.213).Possible role of aspirin in the cases of TMB was reported in 2 studies. In first study aspirin compared with placebo.<sup>8</sup> In this study aspirin showed statistically insignificant reduction in stroke rate after 3 months and significant reduction in mortality rate.

The second study was with 3 parallel arms (low- and high-dose aspirin and placebo).<sup>13,14</sup>

This study showed no impact on mortality and morbidity. Outcomes in the high-dose aspirin group compared favourably with the other treatment groups despite younger age and more severe neurological involvement.<sup>15</sup> Aspirin has also been found to be associated with 19.1% absolute risk reduction in ischemic stroke and 22% absolute risk reduction in mortality of TBM.<sup>8</sup> The observed reduction in the frequency of stroke may be due to antiplatelet and antithrombotic effects of aspirin.<sup>16</sup>

### CONCLUSION:

In children with TBM stage III, aspirin resulted in reduction in mortality but did not achieve statistical significance. Further studies with large sample size could ensure better understanding and outcome for the role of aspirin in children with TBM.

### REFERENCES:

1. World Health organization. Global tuberculosis report 2014. Geneva: World Health organization; 2014.
2. Codlin AJ, Khowaja S, Chen Z, Rahbar MH, Qadeer E, Ara I, et al. Short report: Gender differences in tuberculosis notification in Pakistan. *Am J Trop Med Hyg* 2011;85(3):514-7.
3. Pakistan Paediatric Association. Guidelines for diagnosis and management of tuberculosis in children. 1st edition. Lahore: Pakistan Paediatric Association; 2006.
4. Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. *Lancet Infect Dis* 2014;14(10):947-57.
5. Kalita J, Nair PP, Misra UK. Predictors of stroke and its significance in the outcome of tuberculous meningitis. *J Stroke Cerebrovasc Dis* 2009;18(4):251-8.
6. Iype T, Chacko S, Raghavan S, Mathew R, Mohan M. Preliminary report of directly observed treatment, short course in tuberculous meningitis. *Ann Indian AcadNeurol* 2010;13(1):57-60
7. Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. *J NeurolSci* 2011;303(1-2):22-30.
8. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. *J NeurolSci* 2010;293(1-2).
9. Starke JR, Tuberculosis. In: Jensen HB, Baltimore RS, editors. *Pediatric infectious diseases: principles and practices*. Philadelphia: WB Saunders; 2002. p. 396-419.
10. Donald PR, Schaaf HS, Schoeman JF. Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited. *J Infect*. 2005;50:193– 5.
11. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of childhood tuberculosis in a highly endemic area. *Int J Tuberc Lung Dis*. 2006;10:732-8.
12. Schoeman JF, Janse van Rensburg A, Laubscher JA, Springer P. The role of aspirin in childhood tuberculous meningitis. *J Child Neurol*. 2011;26:956–62.
13. Starke JR. Pediatric tuberculosis: time for a new approach. *Tuberculosis (Edinb)* 2003;83:208-12.
14. Yaramis A, Gurkan F, Elevli M, Soker M, Haspolat K, Kirbas G, et al. Central nervous system tuberculosis in children: a review of 214 cases. *Pediatrics* 1998;102:E49.
15. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986. *Int J Tuberc Lung Dis*. 1999;3:S231–79.
16. World Health Organization. *Treatment of tuberculosis: guidelines for national programmes*. Geneva: World Health Organization; 2003. WHO/CDS/TB/2003.313.